학술논문

Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood.(vol 136, pg 2994, 2020)
Document Type
Journal
Source
BLOOD; JUN 29 2023, 141 26, p3232-p3232, 1p.
Subject
Language
English
ISSN
15280020